Journal
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
Volume 18, Issue -, Pages 447-456Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/TCRM.S348724
Keywords
treatment; migraine; CGRP; gepant
Categories
Ask authors/readers for more resources
Advances in molecular biology and neuroscience have led to the discovery of CGRP and its role in migraine. Gepants, including atogepant, are oral medications that inhibit CGRP receptors to prevent migraine attacks and neurogenic inflammation.
Advances in molecular biology and neuroscience have led to the discovery of calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide that plays a critical role in the pathogenesis of migraine. CGRP receptor antagonist, also known as gepant, is an oral medication that inhibits the CGRP-related nociceptive signaling pathway. To date, three gepants are approved by the FDA for migraine treatment. Atogepant is a 2nd-generation gepant that non-competitively antagonizes CGRP receptors inhibiting neurogenic inflammation and pain sensitization. With its long half-life and minimal cardiovascular or liver toxicity, it is the first in its class approved primarily for migraine prevention. This article will discuss the evidence, safety, and rationale of atogepant for use in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available